UBS Group
BEAM icon

UBS Group’s Beam Therapeutics BEAM Stock Holding History

UBS Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-49,600
Closed -$3.97M – 9382
2021
Q1 		$3.97M Buy
+49,600
New +$4.72M ﹤0.01% 2860

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

UBS Group's BEAM Position: Q1 2026 in Review

UBS Group reduced its Beam Therapeutics (BEAM) stake by 15% in Q1 2026, selling an estimated $4.1M and leaving 826,061 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2607.

UBS Group first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $45.1M in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • UBS Group held 826,061 shares of Beam Therapeutics worth $19.7M as of Q1 2026.
  • UBS Group sold 147,782 Beam Therapeutics shares in Q1 2026, an estimated $4.1M.
  • Beam Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2607 holding.
  • UBS Group first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • UBS Group's Beam Therapeutics position peaked at $45.1M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.